

March 9, 1970

Dr. Joan Ciambalvo
Smith, Kline & French Laboratories
Philadelphia, Pa.

Dear Dr. Ciambalvo,

I have just read the latest newsletter of the DIA, and noted the call for papers for the September meeting. I am not sure that the work which we are now completing is of direct interest to the Association, but it may be useful for you to consider the EEG profile analysis of psychoactive drugs as a classification procedure. As you may recollect, we have been active in defining drug specific EEG patterns in patients and in normal volunteers, in an effort to define the characteristics of new compounds before they have gone through extensive and expensive clinical trials. The work has had some interesting results, notably in the classification of cyclazocine as an antidepressant, doxepin as an antidepressant, fenfluramine as a sedative anorexigenic, etc.

If there is a panel or symposium dedicated to novel methods of assay of psychoactive drugs; or, with an emphasis on the types of novel data analyses that may be useful in the next few years for psychopharmacology, perhaps you would consider a presentation by my associates and myself, on the general topic of "EEG Profile Analysis as a Classification of Psychoactive Drugs".

Thank you for your consideration.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

Mf/